Drug intelligence / Profile preview

Yangzheng Heji

Development stage: Unknown
Lead developer: Shanxi Buchang Pharmaceutical
Administration: Oral

Overview

Yangzheng Heji is a Traditional Chinese Medicine (TCM) oral liquid developed and manufactured by Shanxi Buchang Pharmaceutical. It is approved in China for use in cancer and tumor supportive care. The formulation is designed according to TCM principles to tonify Qi, nourish Yin, and strengthen the spleen and kidneys. In clinical practice, it is primarily used as an adjuvant therapy to improve the quality of life, enhance immune function, and mitigate the side effects (such as fatigue and leucopenia) in patients undergoing chemotherapy or radiotherapy for various malignancies.

Brand names: Yangzheng Heji
Other names: 养正合剂Yangzheng oral liquid

Beyond the preview

Go deeper on Yangzheng Heji.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Yangzheng Heji.

Explore the full profile